Evogene (EVGN) FCF Margin (2013 - 2026)

Evogene (EVGN) posted FCF Margin of 883.83% for Q1 2026, down 3.55% sequentially from 853.5% in Q4 2025, and down 66783.0% YoY from N/an in Q1 2025.

Evogene (EVGN) FCF Margin (2013 - 2026) Analysis & Trends

Evogene has reported FCF Margin for 14 years, with the latest figure at 883.83% in Q1 2026.

Quarterly FCF Margin fell 66783.0% year-over-year to 883.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 437.58% (down 29610.0% YoY) and the FY2025 annual result came in at 346.92%, up 1754.0% from the prior year.
FCF Margin retreated to 883.83% in Q1 2026 per EVGN's latest filing, from 853.5% in the prior quarter.
Over five years, FCF Margin peaked at 3065.4% in Q1 2022 and troughed at 2036.22% in Q2 2022.
A 5-year average of 89.07% and a median of 261.54% in 2025 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 441855 bps in 2022, down 674659 bps in 2022.
Over 5 years, FCF Margin stood at 372.12% in 2022, then soared by 371 bps to 1010.21% in 2023, then tumbled by 127 bps to 274.72% in 2024, then sank by 211 bps to 853.5% in 2025, then fell by 4 bps to 883.83% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 883.83%, 853.5%, and 40.06% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	-883.83%

Download Data